KYAT1 Dysfunction and Disease (G883)

Target Name: KYAT1

NCBI ID: G883

KYAT1

KYAT1 Dysfunction and Disease

KYAT1 (Glutamine-phenylpyruvate aminotransferase) is a protein that is expressed in various tissues of the body, including the liver, muscle, and pancreas. It is a member of the superfamily of amino acid transporters, which are a group of transmembrane proteins that play a crucial role in the transport of amino acids across cell membranes. KYAT1 is involved in the transport of glutamine and phenylpyruvate aminotransferase (PPA) across the cell membrane, and its function in this process has been studied extensively in the context of various diseases, including cancer , obesity, and neurodegenerative diseases.

Diseases associated with KYAT1 dysfunction

KYAT1 dysfunction has been implicated in the development and progression of several diseases, including cancer, obesity, and neurodegenerative diseases.

1.Cancer

KYAT1 has been shown to be involved in the regulation of cell proliferation, and its dysfunction has been linked to the development of various types of cancer. For example, studies have shown that KYAT1 is expressed in various types of cancer, including breast, lung, and colon cancer. Additionally, KYAT1 has been shown to play a role in the development of neuroendocrine cancer, a type of cancer that arises from the neuroendocrine tumors.

2. Obesity

KYAT1 has also been shown to be involved in the regulation of body weight and obesity. Several studies have shown that individuals with obesity are less likely to have functional KYAT1 than those who are of a normal weight. Additionally, studies have shown that KYAT1 dysfunction is associated with an increased risk of obesity-related diseases, such as type 2 diabetes and cardiovascular disease.

3. Neurodegenerative diseases

KYAT1 has also been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that individuals with neurodegenerative diseases are less likely to have functional KYAT1 than those who are healthy. Additionally, studies have shown that KYAT1 Dysfunction is associated with an increased risk of neurodegenerative diseases, such as the development of neurofibrillary tangles and neurodegeneration.

4. Other diseases

KYAT1 dysfunction has also been implicated in the development and progression of other diseases, including respiratory diseases, urologic diseases, and neuropsychiatric diseases.

Conclusion

In conclusion, KYAT1 is a protein that is involved in the transport of glutamine and phenylpyruvate aminotransferase across the cell membrane. Its dysfunction has been implicated in the development and progression of several diseases, including cancer, obesity, and neurodegenerative diseases. Further research is needed to fully understand the role of KYAT1 in these diseases and to develop effective treatments.

Protein Name: Kynurenine Aminotransferase 1

Functions: Catalyzes the irreversible transamination of the L-tryptophan metabolite L-kynurenine to form kynurenic acid (KA), an intermediate in the tryptophan catabolic pathway which is also a broad spectrum antagonist of the three ionotropic excitatory amino acid receptors among others (PubMed:19338303, PubMed:28097769). Also metabolizes the cysteine conjugates of certain halogenated alkenes and alkanes to form reactive metabolites (PubMed:7883047). Catalyzes the beta-elimination of S-conjugates and Se-conjugates of L-(seleno)cysteine, resulting in the cleavage of the C-S or C-Se bond (PubMed:7883047)

The "KYAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KYAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets